Minimal change disease onset observed after bevacizumab administration

This is a report of a patient with minimal change disease (MCD) onset after bevacizumab administration. A 72-year-old man with inoperable Grade 3 astrocytoma was treated with a combination of temozolomide and the vascular endothelial growth factor monoclonal antibody bevacizumab. After two biweekly...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Ramy M., Lopez, Eduardo, Wilson, James, Barathan, Shrinath, Cohen, Arthur H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Glomerulonephritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792614/
https://www.ncbi.nlm.nih.gov/pubmed/26985375
http://dx.doi.org/10.1093/ckj/sfv139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792614/
https://www.ncbi.nlm.nih.gov/pubmed/26985375
http://dx.doi.org/10.1093/ckj/sfv139

Ejemplares similares